E. Ohman J or Asset Management AB Has $37.43 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

E. Ohman J or Asset Management AB lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 155,238 shares of the medical instruments supplier’s stock after selling 5,655 shares during the period. Becton, Dickinson and Company makes up approximately 0.9% of E. Ohman J or Asset Management AB’s portfolio, making the stock its 29th biggest holding. E. Ohman J or Asset Management AB owned about 0.05% of Becton, Dickinson and Company worth $37,428,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. Jennison Associates LLC increased its position in shares of Becton, Dickinson and Company by 4.9% during the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the last quarter. Norden Group LLC raised its position in Becton, Dickinson and Company by 2,086.7% in the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after acquiring an additional 49,559 shares during the period. Avity Investment Management Inc. raised its position in Becton, Dickinson and Company by 3.5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after acquiring an additional 5,527 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Becton, Dickinson and Company by 9.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock valued at $14,481,000 after acquiring an additional 5,006 shares during the last quarter. Finally, Axxcess Wealth Management LLC grew its position in shares of Becton, Dickinson and Company by 30.2% during the 1st quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock valued at $2,735,000 after acquiring an additional 2,565 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on BDX. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $238.62 on Friday. The stock’s 50 day moving average is $237.33 and its 200 day moving average is $235.16. The company has a market capitalization of $68.96 billion, a P/E ratio of 52.56, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.96 earnings per share. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.